| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
High rate of complete histopathological response in hepatocellular carcinoma patients after combined transarterial chemoembolization and stereotactic body radiation therapy
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Ulrike Bauer, Sabine Gerum, Falk Roeder, Stefan Münch, Stephanie E Combs, Alexander B Philipp, Enrico N De Toni, Martha M Kirstein, Arndt Vogel, Carolin Mogler, Bernhard Haller, Jens Neumann, Rickmer F Braren, Marcus R Makowski, Philipp Paprottka, Markus Guba, Fabian Geisler, Roland M Schmid, Andreas Umgelter and Ursula Ehmer |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ursula Ehmer, MD, PhD, Doctor, Doctor, Internal Medicine II, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Str. 21, Munich 81675, Germany. ursula.ehmer@tum.de |
| Key Words |
Hepatocellular carcinoma; Transarterial chemoembolization; Stereotactic body radiation therapy; Bridging therapy; Liver transplantation |
| Core Tip |
In patients with early-stage hepatocellular carcinoma (HCC) who are not eligible for resection or ablation, liver transplantation presents a curative treatment option. To halt tumor growth during waiting time, bridging therapies such as transarterial chemoembolization (TACE), ablation, and stereotactic body radiation therapy (SBRT) are used prior to liver transplantation. In a multicenter retrospective trial with 27 HCC patients who received either TACE or SBRT alone, or a combination of TACE and SBRT, explant histopathology was analyzed to assess treatment response. Strikingly, almost all patients in the combination group exhibited no residual vital tumor by histopathology, whereas TACE or SBRT alone resulted in significantly lower rates of complete histopathological response. |
| Publish Date |
2021-06-25 09:46 |
| Citation |
Bauer U, Gerum S, Roeder F, Münch S, Combs SE, Philipp AB, De Toni EN, Kirstein MM, Vogel A, Mogler C, Haller B, Neumann J, Braren RF, Makowski MR, Paprottka P, Guba M, Geisler F, Schmid RM, Umgelter A, Ehmer U. High rate of complete histopathological response in hepatocellular carcinoma patients after combined transarterial chemoembolization and stereotactic body radiation therapy. World J Gastroenterol 2021; 27(24): 3630-3642 |
| URL |
https://www.wjgnet.com/1007-9327/full/v27/i24/3630.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v27.i24.3630 |
